Minimal residual disease (MRD) monitoring in chronic myelogenous leukemia (CML) patients treated with STI571 (Glivec®)

被引：0
|
作者：
Roche-Lestienne, C
Grardel-Duflos, N
Cornu-Soenen, V
Laï, JL
Roumier, C
Berthaud, P
Cosson, A
Facon, T
Preudhomme, C
机构：
来源：
LEUKEMIA | 2001年 / 15卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2023 / 2023
页数：1
相关论文
共 50 条
  • [31] Treatment response to Glivec® (formerly STI571) in a patient with p185 BCR/ABLpositive chronic melogenous leukaemia (CML).
    Al-Ali, HK
    Pufe, B
    Reinhold, U
    Leiblein, S
    Gschaidmeier, H
    Niederwieser, DW
    Deininger, MW
    BLOOD, 2001, 98 (11) : 254B - 254B
  • [32] Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia
    Savona, Michael R.
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (05): : 171 - 178
  • [33] Treatment with STI571 (Novartis®) in chronic myeloid leukemia (CML):: Unexpected hematological findings in a series of 26 patients.
    Meunier, V
    Giraudier, S
    Van den Akker, J
    Perot, C
    Jouault, H
    Caron-Servan, B
    Robin, V
    Tulliez, M
    Imbert, M
    BLOOD, 2001, 98 (11) : 263B - 263B
  • [34] Results of imatinib mesylate (STI571) therapy in patients (pts) with chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (allo SCT).
    Kantarjian, HM
    O'Brien, S
    Cortes, J
    Giralt, S
    Rios, MB
    Shan, J
    Giles, F
    Thomas, D
    Faderl, S
    de Lima, M
    Arlinghaus, RB
    Garcia-Manero, G
    Issa, JP
    Resta, D
    Capdeville, R
    Talpaz, M
    BLOOD, 2001, 98 (11) : 137A - 137A
  • [35] Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)
    Thiele, J
    Kvasnicka, HM
    Varus, E
    Kriener, S
    Engels, K
    Staib, P
    Ollig, ES
    Griesshammer, M
    Waller, CF
    Pfeifer, H
    Schmitt-Gräff, A
    PATHOLOGE, 2004, 25 (06): : 428 - 435
  • [36] Effects of the tyrosine kinase inhibitor Imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia
    Thiele, J
    Kvasnicka, HM
    Schmitt-Graeff, A
    Kriener, S
    Engels, K
    Staib, P
    Griesshammer, M
    Waller, CF
    Ottmann, OG
    Hansmann, M
    HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (04) : 1277 - 1288
  • [37] Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
    Cumbo, Cosimo
    Anelli, Luisa
    Specchia, Giorgina
    Albano, Francesco
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3175 - 3189
  • [38] Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia
    K. Miyachi
    A. Ihara
    R. W. Hankins
    R. Murai
    S. Maehiro
    H. Miyashita
    Clinical Rheumatology, 2003, 22 : 329 - 332
  • [39] The tyrosine kinase inhibitor STI571 prolongs survival in a murine model of chronic myelogenous leukemia.
    Wolff, NC
    Xu, HM
    Zhang, SM
    Ilaria, RL
    BLOOD, 2000, 96 (11) : 344A - 344A
  • [40] Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia
    Miyachi, K
    Ihara, A
    Hankins, RW
    Murai, R
    Maehiro, S
    Miyashita, H
    CLINICAL RHEUMATOLOGY, 2003, 22 (4-5) : 329 - 332
12345